Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial - PubMed
5 days ago
- #immunotherapy
- #metastatic uveal melanoma
- #clinical trial
- Percutaneous hepatic perfusion combined with ipilimumab and nivolumab (CHOPIN trial) evaluated for metastatic uveal melanoma.
- Primary endpoint: 1-year progression-free survival significantly improved with combination therapy (54.7%) vs. perfusion alone (15.8%).
- Higher incidence of grade 3-4 adverse events in the combination group (82%) compared to perfusion alone (41%).
- Common severe adverse events included thrombocytopenia, leukopenia, γ-glutamyl transferase increase, and anemia.
- One treatment-related death occurred in the combination group due to triple M syndrome.
- Combination therapy presents a promising new treatment paradigm but requires validation in larger trials.
- Funding provided by Leiden University Medical Centre, Delcath Systems, and Bristol Myers Squibb.